{"organizations": [], "uuid": "917840d2f14a2629920f069546a1f20151f7cdb7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180130.html", "section_title": "Archive News &amp; Video for Tuesday, 30 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-ab-biosciences-and-shire-enter-int/brief-ab-biosciences-and-shire-enter-into-agreement-idUSFWN1PP10X", "country": "US", "domain_rank": 408, "title": "BRIEF-AB Biosciences And Shire Enter Into Agreement", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.999, "site_type": "news", "published": "2018-01-30T20:12:00.000+02:00", "replies_count": 0, "uuid": "917840d2f14a2629920f069546a1f20151f7cdb7"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ab-biosciences-and-shire-enter-int/brief-ab-biosciences-and-shire-enter-into-agreement-idUSFWN1PP10X", "ord_in_thread": 0, "title": "BRIEF-AB Biosciences And Shire Enter Into Agreement", "locations": [], "entities": {"persons": [{"name": "shire", "sentiment": "none"}], "locations": [], "organizations": [{"name": "shire plc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "mmercialization of ab biosciences", "sentiment": "none"}, {"name": "shire plc - ‍ab biosciences", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 30 (Reuters) - Shire Plc:\n* AB BIOSCIENCES AND SHIRE ENTER INTO AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF AB BIOSCIENCES’ PRIM PROGRAM\n* SHIRE PLC - NO FURTHER TERMS OF AGREEMENT WERE DISCLOSED * SHIRE PLC - ‍AB BIOSCIENCES TO RECEIVE AN UPFRONT LICENSE FEE AND POTENTIAL RESEARCH, DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS FROM SHIRE​\n* SHIRE PLC - SHIRE RECEIVES EXCLUSIVE WORLDWIDE LICENSE TO DEVELOP AND COMMERCIALIZE PRIM PROGRAM Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-30T20:12:00.000+02:00", "crawled": "2018-01-31T16:09:39.001+02:00", "highlightTitle": ""}